TCM
ADCT icon

TCG Crossover Management’s ADC Therapeutics ADCT Stock Holding History

TCG Crossover Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Hold
11,390,175
– – 0.29% 44
2026
Q1 		$42.7M Hold
11,390,175
– – 1.22% 22
2025
Q4 		$40.2M Buy
11,390,175
+10,000,000
+719% +$40.6M 1.33% 22
2025
Q3 		$5.56M Buy
+1,390,175
New +$4.38M 0.27% 37

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCG Crossover Management's ADCT Position: Q2 2026 in Review

TCG Crossover Management held its ADC Therapeutics (ADCT) position steady in Q2 2026 at 11,390,175 shares worth $12.2M. The position accounts for 0.29% of the portfolio, ranked #44.

TCG Crossover Management first reported a position in ADCT in Q3 2025 and has held it in 4 quarters since. The position peaked at $42.7M in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • TCG Crossover Management held 11,390,175 shares of ADC Therapeutics worth $12.2M as of Q2 2026.
  • TCG Crossover Management left its ADC Therapeutics share count unchanged in Q2 2026.
  • ADC Therapeutics made up 0.29% of TCG Crossover Management's portfolio in Q2 2026, its #44 holding.
  • TCG Crossover Management first reported a position in ADC Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • TCG Crossover Management's ADC Therapeutics position peaked at $42.7M in Q1 2026.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.